Merck & Company Inc (MRK) - Stock Report

Latest Proof Snapshot: Q1 2026 sales rose 5% to $16.3 bn, led by KEYTRUDA/KEYTRUDA QLEX at $8.0 bn and WINREVAIR at $525 mn, while Animal Health reached $1.8 bn. The same quarter also exposed the replacement burden: GARDASIL/GARDASIL 9 fell 19%, JANUVIA/JANUMET fell 28%, and reported net income turned into a $4.2 bn loss after the Cidara acquisition charge. Reported operating cash flow was $3.9 bn and capex was $1.0 bn, leaving a $2.9 bn post-capex cash proxy against $3.0 bn of dividends and buybacks.

The owner test is therefore sector-specific: Merck must show that operating cash flow, struck after R&D, can stay large enough after capex to fund the dividend, debt service, selective M&A, and pipeline investment while Keytruda moves toward biosimilar competition and IRA price negotiation risk. The current evidence is strong enough to keep Merck on the watchlist, but not strong enough to lift the selected fair-value anchor.

The key macro issue is not healthcare pricing pressure in the abstract, but whether Keytruda's 2028-2029 exclusivity and pricing reset can be bridged through lifecycle management, new launches, Gardasil stabilization and acquired assets into post-capex cash before dividend cover and balance-sheet flexibility tighten.

Merck is a research-based biopharmaceutical company with two reportable segments: Pharmaceutical and Animal Health. Pharmaceutical is the economic center of the company; it sells oncology therapies, vaccines, cardiometabolic and respiratory medicines, hospital acute-care products, virology products, diabetes therapies, and alliance assets. Animal Health provides livestock and companion-animal medicines and vaccines, a smaller but less Keytruda-dependent cash stream.

The value stack starts with Keytruda, Merck's anti-PD-1 oncology franchise, because it supplies scale, specialist access, clinical-data breadth, and manufacturing leverage. Vaccines such as Gardasil and Gardasil 9 add prevention-driven volume but are more exposed to China demand and public-sector purchasing patterns. WINREVAIR and OHTUVAYRE are the main cardiopulmonary bridge assets, while Animal Health adds a steadier, non-human-health platform with Bravecto and livestock demand.

This is a mixed branded-therapy and vaccine portfolio, not a pure biologics story. Keytruda is a biologic and faces biosimilar risk; Januvia and Janumet are small-molecule diabetes products and face generic and pricing pressure. That distinction matters because the erosion mechanisms, timing, and gross-margin impact differ.